2022 Revenues ($USD) : $4,416,740,000
2022 Revenues (foreign currencies) : € 3,743,000,000
2022 R&D spend : $260,780,000
2022 Number of Employees : 30,000
Fiscal Year End : 12/31/2021
Company CEO : Rice Powell, CEO; Carla Kriwet, incoming CEO; Dr. Katarzyna Mazur-Hofsäß, CEO of Care Enablement for Fresenius Medical Care

Fresenius Medical Care is one of the world’s top providers of products and services for people with renal diseases. Severe COVID-19 cases can cause acute kidney failure, so Fresenius Medical Care expanded production of acute dialysis products at short notice at the start of the pandemic. Around the same time, FDA cleared the company’s Novalung system — which reduces or eliminates the need for mechanical ventilation by pumping a person’s blood through an oxygenator for gas exchange. In 2022, Fresenius Medical Care hired Carla Kriwet as CEO to replace longtime leader Rice Powell, who will retire at the end of the year. The company also spun off its Fresenius Health Partners division in a three-way merger with InterWell Health and Cricket Health. The new company provides kidney care under the InterWell Health brand. –CN and JH